Mary DiBiase

CIK: 0001880179

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XFOR

X4 Pharmaceuticals, Inc

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

XFOR
X4 Pharmaceuticals, Inc
Feb 12, 2025
Award(A)
Direct
650K shares-
XFOR
X4 Pharmaceuticals, Inc
Jan 24, 2025
Sale(S)
Direct
22.3K shares at avg. $0.45$10K
XFOR
X4 Pharmaceuticals, Inc
Jan 23, 2025
Award(A)
Direct
61.2K shares-
XFOR
X4 Pharmaceuticals, Inc
Oct 7, 2024
Sale(S)
Direct
67.7K shares at avg. $0.57$38K
XFOR
X4 Pharmaceuticals, Inc
Oct 4, 2024
Award(A)
Direct
230.6K shares-
XFOR
X4 Pharmaceuticals, Inc
Sep 9, 2024
Sale(S)
Direct
2.6K shares at avg. $0.66$2K

		Type	Shares	Price		Ownership
Feb 12, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	650,000	-	-	Direct
Jan 24, 2025	XFOR X4 Pharmaceuticals, Inc	Sale(S)	22,258	$0.45	$10,094	Direct
Jan 23, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	61,178	-	$0	Direct
Oct 7, 2024	XFOR X4 Pharmaceuticals, Inc	Sale(S)	67,695	$0.57	$38,329	Direct
Oct 4, 2024	XFOR X4 Pharmaceuticals, Inc	Award(A)	230,645	-	$0	Direct
Sep 9, 2024	XFOR X4 Pharmaceuticals, Inc	Sale(S)	2,642	$0.66	$1,738	Direct

1-6 of 6 transactions

About DiBiase Mary

DiBiase Mary (SEC CIK 0001880179) files insider reports with the SEC as Chief Operating Officer of X4 Pharmaceuticals, Inc (XFOR).

Signal8 holds 4 ownership filings by DiBiase Mary, all Form 4s, filed between Sep 11, 2024 and Feb 14, 2025. Those filings report 6 transactions, from Sep 9, 2024 to Feb 12, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on DiBiase Mary's filings is in BOSTON, MA.

Recent filings by DiBiase Mary

Feb 12, 2025: Grant or award of XFOR shares (Form 4, code A).
Jan 24, 2025: Open-market sale of XFOR shares (Form 4, code S).
Jan 23, 2025: Grant or award of XFOR shares (Form 4, code A).
Oct 7, 2024: Open-market sale of XFOR shares (Form 4, code S).
Oct 4, 2024: Grant or award of XFOR shares (Form 4, code A).

Other insiders filing for X4 Pharmaceuticals, Inc (XFOR)

Craig Adam R, Executive Chairman
KIRSKE DAVID, Chief Financial Officer
Volpone John, President
Gold Kelly, Director
Bridger Gary, Director
de Craecker Francoise, Director

How to read Form 4 transaction codes